It has been an exciting few weeks at Americord. Earlier this month we announced the establishment of our corporate giving program, and just this week we made our first donation to support a new clinical trial studying the treatment of Alzheimer’s Disease with a stem cell therapy. Americord’s funding went to MEDIPOST, a leading stem cell biotechnology company that is studying the safety and efficacy of NEUROSTEM-AD®, a treatment agent for Alzheimer’s Disease that uses human umbilical cord blood-derived mesenchymal stem cells.
We established our corporate giving program so we can provide financial assistance to top scientists around the world who are pursuing stem cell-based treatments for diseases that have been hard or impossible to treat. This includes, but is not limited to, Alzheimer’s Disease, a disease that continues to bring suffering to so many families. MEDIPOST is just one of many companies who are exploring the cutting edge of medical treatments using stem cells. We hope to fund many more leading scientists in coming months and years as they pursue stem cell-based treatments for everything from spinal cord injuries to heart disease.
Read more about Americord’s first corporate giving donation here.
The post Americord Funds its First Clinical Trial appeared first on The Cord Blood Blog.
